As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
Explore Our solutions in our A-Z pharmaceutical Brand catalogue.
View by-
The biologics vertical was conceptualized in the year 2009. With the identification of key Biosimilars and helmed by a multi-disciplinary team of over 200 specialists, R&D commenced soon at the Hetero Research Foundation(HRF). Hetero Biosimilars has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (mABs).Hetero has successfully launched Biosimilars of Darbepoetin alfa, Rituximab, Bevacizumab and Adalimumab and also has an ambitious pipeline of other Biosimilars.With this strength in Biosimilars "ASRA" division was carved out to serve the patients in need of Biosimilars for treating rheumatologic conditions.Over 2000 patients in India in the field of Rheumatology & Dermatolgy, are benefited by MABURA & MABAL-RA Biosimilars of Adalimumab and Rituximab and still going strong.
